Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial

Alector and GSK's potential dementia drug, latozinemab (AL001), failed a Phase 3 clinical trial in frontotemporal dementia (FTD) patients with a specific gene mutation1234.

The drug did not meet its primary endpoint of slowing disease progression and showed no significant treatment-related effect on secondary or exploratory measures12.

Following the results, Alector will discontinue development of latozinemab for FTD and stop related extension studies124.

Alector announced plans to cut nearly half its workforce (49%) and its research and development chief resigned effective December 22, 20251.

The drug succeeded in raising plasma progranulin—a protein thought to play a role in brain health—but this increase did not translate into meaningful clinical benefits1.

Alector's shares dropped 51% after the news, and several Wall Street analysts downgraded the stock1.

Alector and GSK are continuing to advance another progranulin-targeted drug (nivisnebart/AL101) in an ongoing Phase 2 Alzheimer’s disease trial, with interim results expected next year1.

The failed trial was known as Infront-3 and patients received monthly infusions of latozinemab or placebo for 96 weeks13.

Sources:

1. https://www.biopharmadive.com/news/gsk-alector-frontotemporal-dementia-latozinemab-study-results/803463/

2. https://lifescivoice.com/alector-ends-development-of-gsk-partnered-latozinemab-after-phase-3-failure-in-ftd/

3. https://firstwordpharma.com/story/6376879

4. https://global.morningstar.com/en-gb/news/alliance-news/1761124923901930600/gsk-halts-dementia-study-after-trial-results-moves-ahead-with-inhaler